<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32353955</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2073-4425</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>11</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Apr</Month>
              <Day>28</Day>
            </PubDate>
          </JournalIssue>
          <Title>Genes</Title>
          <ISOAbbreviation>Genes (Basel)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">477</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/genes11050477</ELocationID>
        <Abstract>
          <AbstractText>Neurofibromatosis Type 1 (NF1) is a common genetic disorder and cancer predisposition syndrome (1:3000 births) caused by mutations in the tumor suppressor gene <i>NF1</i>. <i>NF1</i> encodes neurofibromin, a negative regulator of the Ras signaling pathway. Individuals with NF1 often develop benign tumors of the peripheral nervous system (neurofibromas), originating from the Schwann cell linage, some of which progress further to malignant peripheral nerve sheath tumors (MPNSTs). Treatment options for neurofibromas and MPNSTs are extremely limited, relying largely on surgical resection and cytotoxic chemotherapy. Identification of novel therapeutic targets in both benign neurofibromas and MPNSTs is critical for improved patient outcomes and quality of life. Recent clinical trials conducted in patients with NF1 for the treatment of symptomatic plexiform neurofibromas using inhibitors of the mitogen-activated protein kinase (MEK) have shown very promising results. However, MEK inhibitors do not work in all patients and have significant side effects. In addition, preliminary evidence suggests single agent use of MEK inhibitors for MPNST treatment will fail. Here, we describe the preclinical efforts that led to the identification of MEK inhibitors as promising therapeutics for the treatment of NF1-related neoplasia and possible reasons they lack single agent efficacy in the treatment of MPNSTs. In addition, we describe work to find targets other than MEK for treatment of MPNST. These have come from studies of RAS biochemistry, in vitro drug screening, forward genetic screens for Schwann cell tumors, and synthetic lethal screens in cells with oncogenic <i>RAS</i> gene mutations. Lastly, we discuss new approaches to exploit drug screening and synthetic lethality with <i>NF1</i> loss of function mutations in human Schwann cells using CRISPR/Cas9 technology.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Williams</LastName>
            <ForeName>Kyle B</ForeName>
            <Initials>KB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Largaespada</LastName>
            <ForeName>David A</ForeName>
            <Initials>DA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 NS115438</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01NS086219</GrantID>
            <Acronym>NH</Acronym>
            <Agency>NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>1UG3CA244687</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>04</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Genes (Basel)</MedlineTA>
        <NlmUniqueID>101551097</NlmUniqueID>
        <ISSNLinking>2073-4425</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C000630044">NF1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D025542">Neurofibromin 1</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019070" MajorTopicYN="N">Cell Lineage</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064593" MajorTopicYN="N">Heterografts</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058990" MajorTopicYN="Y">Molecular Targeted Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009456" MajorTopicYN="N">Neurofibromatosis 1</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025542" MajorTopicYN="N">Neurofibromin 1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018319" MajorTopicYN="N">Neurofibrosarcoma</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012583" MajorTopicYN="N">Schwann Cells</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Schwann cells</Keyword>
        <Keyword MajorTopicYN="Y">genetically engineered mouse models</Keyword>
        <Keyword MajorTopicYN="Y">malignant peripheral nerve sheath tumors</Keyword>
        <Keyword MajorTopicYN="Y">neurofibromatosis type 1 syndrome</Keyword>
        <Keyword MajorTopicYN="Y">neurofibromin 1</Keyword>
        <Keyword MajorTopicYN="Y">plexiform neurofibromas</Keyword>
      </KeywordList>
      <CoiStatement>D.A.L. is the co-founder and co-owner of several biotechnology companies including NeoClone Biotechnologies, Inc., Discovery Genomics, Inc. (recently acquired by Immusoft, Inc.), B-MoGen Biotechnologies, Inc. (recently acquired by the biotechne corporation), and Luminary Therapeutics, Inc. He consults for Genentech, Inc., which is funding some of his research. D.A.L. holds equity in and serves as the Chief Scientific Officer of Surrogen, a subsidiary of Recombinetics, a genome-editing company. The business of all these companies is unrelated to the contents of this manuscript. K.B.W. has no conflicts of interest to disclose.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>4</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32353955</ArticleId>
        <ArticleId IdType="pmc">PMC7290716</ArticleId>
        <ArticleId IdType="doi">10.3390/genes11050477</ArticleId>
        <ArticleId IdType="pii">genes11050477</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Gutmann D.H., Ferner R.E., Listernick R.H., Korf B.R., Wolters P.L., Johnson K.J. Neurofibromatosis type 1. Nat. Rev. Dis Primers. 2017;3:17004. doi: 10.1038/nrdp.2017.4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrdp.2017.4</ArticleId>
            <ArticleId IdType="pubmed">28230061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernandez-Martin A., Duat-Rodriguez A. An Update on Neurofibromatosis Type 1: Not Just Cafe-au-Lait Spots and Freckling. Part II. Other Skin Manifestations Characteristic of NF1. NF1 and Cancer. Actas Dermosifiliogr. 2016;107:465–473. doi: 10.1016/j.adengl.2016.05.019.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.adengl.2016.05.019</ArticleId>
            <ArticleId IdType="pubmed">26956402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Longo J.F., Weber S.M., Turner-Ivey B.P., Carroll S.L. Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms. Adv. Anat. Pathol. 2018;25:353–368. doi: 10.1097/PAP.0000000000000197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/PAP.0000000000000197</ArticleId>
            <ArticleId IdType="pubmed">29762158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brosseau J.P., Liao C.P., Wang Y., Ramani V., Vandergriff T., Lee M., Patel A., Ariizumi K., Le L.Q. NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. Nat. Commun. 2018;9:5014. doi: 10.1038/s41467-018-07452-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-07452-y</ArticleId>
            <ArticleId IdType="pmc">PMC6258697</ArticleId>
            <ArticleId IdType="pubmed">30479396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miettinen M.M., Antonescu C.R., Fletcher C.D.M., Kim A., Lazar A.J., Quezado M.M., Reilly K.M., Stemmer-Rachamimov A., Stewart D.R., Viskochil D., et al.  Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum. Pathol. 2017;67:1–10. doi: 10.1016/j.humpath.2017.05.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.humpath.2017.05.010</ArticleId>
            <ArticleId IdType="pmc">PMC5628119</ArticleId>
            <ArticleId IdType="pubmed">28551330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beert E., Brems H., Daniels B., De Wever I., Van Calenbergh F., Schoenaers J., Debiec-Rychter M., Gevaert O., De Raedt T., Van Den Bruel A., et al.  Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors. Genes Chromosomes Cancer. 2011;50:1021–1032. doi: 10.1002/gcc.20921.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/gcc.20921</ArticleId>
            <ArticleId IdType="pubmed">21987445</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carrio M., Gel B., Terribas E., Zucchiatti A.C., Moline T., Rosas I., Teule A., Ramon Y.C.S., Lopez-Gutierrez J.C., Blanco I., et al.  Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings. Hum. Mutat. 2018;39:1112–1125. doi: 10.1002/humu.23552.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/humu.23552</ArticleId>
            <ArticleId IdType="pubmed">29774626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farid M., Demicco E.G., Garcia R., Ahn L., Merola P.R., Cioffi A., Maki R.G. Malignant peripheral nerve sheath tumors. Oncologist. 2014;19:193–201. doi: 10.1634/theoncologist.2013-0328.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2013-0328</ArticleId>
            <ArticleId IdType="pmc">PMC3926794</ArticleId>
            <ArticleId IdType="pubmed">24470531</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolberg M., Holand M., Agesen T.H., Brekke H.R., Liestol K., Hall K.S., Mertens F., Picci P., Smeland S., Lothe R.A. Survival meta-analyses for &gt;1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro. Oncol. 2013;15:135–147. doi: 10.1093/neuonc/nos287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nos287</ArticleId>
            <ArticleId IdType="pmc">PMC3548581</ArticleId>
            <ArticleId IdType="pubmed">23161774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ratner N., Miller S.J. A RASopathy gene commonly mutated in cancer: The neurofibromatosis type 1 tumour suppressor. Nat. Rev. Cancer. 2015;15:290–301. doi: 10.1038/nrc3911.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3911</ArticleId>
            <ArticleId IdType="pmc">PMC4822336</ArticleId>
            <ArticleId IdType="pubmed">25877329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laycock-van Spyk S., Thomas N., Cooper D.N., Upadhyaya M. Neurofibromatosis type 1-associated tumours: Their somatic mutational spectrum and pathogenesis. Hum. Genom. 2011;5:623–690. doi: 10.1186/1479-7364-5-6-623.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1479-7364-5-6-623</ArticleId>
            <ArticleId IdType="pmc">PMC3525246</ArticleId>
            <ArticleId IdType="pubmed">22155606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jessen W.J., Miller S.J., Jousma E., Wu J., Rizvi T.A., Brundage M.E., Eaves D., Widemann B., Kim M.O., Dombi E., et al.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J. Clin. Invest. 2013;123:340–347. doi: 10.1172/JCI60578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI60578</ArticleId>
            <ArticleId IdType="pmc">PMC3533264</ArticleId>
            <ArticleId IdType="pubmed">23221341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watson A.L., Anderson L.K., Greeley A.D., Keng V.W., Rahrmann E.P., Halfond A.L., Powell N.M., Collins M.H., Rizvi T., Moertel C.L., et al.  Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. Oncotarget. 2014;5:1502–1514. doi: 10.18632/oncotarget.1609.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.1609</ArticleId>
            <ArticleId IdType="pmc">PMC4039227</ArticleId>
            <ArticleId IdType="pubmed">24681606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fischer-Huchzermeyer S., Chikobava L., Stahn V., Zangarini M., Berry P., Veal G.J., Senner V., Mautner V.F., Harder A. Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. BMC Res. Notes. 2018;11:520.  doi: 10.1186/s13104-018-3630-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13104-018-3630-0</ArticleId>
            <ArticleId IdType="pmc">PMC6064132</ArticleId>
            <ArticleId IdType="pubmed">30055648</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peacock J.D., Cherba D., Kampfschulte K., Smith M.K., Monks N.R., Webb C.P., Steensma M. Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. J. Transl. Med. 2013;11:213. doi: 10.1186/1479-5876-11-213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1479-5876-11-213</ArticleId>
            <ArticleId IdType="pmc">PMC3848568</ArticleId>
            <ArticleId IdType="pubmed">24040940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peacock J.D., Pridgeon M.G., Tovar E.A., Essenburg C.J., Bowman M., Madaj Z., Koeman J., Boguslawski E.A., Grit J., Dodd R.D., et al.  Genomic Status of MET Potentiates Sensitivity to MET and MEK Inhibition in NF1-Related Malignant Peripheral Nerve Sheath Tumors. Cancer Res. 2018;78:3672–3687. doi: 10.1158/0008-5472.CAN-17-3167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-3167</ArticleId>
            <ArticleId IdType="pmc">PMC6235171</ArticleId>
            <ArticleId IdType="pubmed">29720369</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ahsan S., Ge Y., Tainsky M.A. Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors. Oncotarget. 2016;7:57171–57185. doi: 10.18632/oncotarget.11036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.11036</ArticleId>
            <ArticleId IdType="pmc">PMC5302981</ArticleId>
            <ArticleId IdType="pubmed">27494873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verdijk R.M., den Bakker M.A., Dubbink H.J., Hop W.C., Dinjens W.N., Kros J.M. TP53 mutation analysis of malignant peripheral nerve sheath tumors. J. Neuropathol. Exp. Neurol. 2010;69:16–26. doi: 10.1097/NEN.0b013e3181c55d55.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0b013e3181c55d55</ArticleId>
            <ArticleId IdType="pubmed">20010306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brohl A.S., Kahen E., Yoder S.J., Teer J.K., Reed D.R. The genomic landscape of malignant peripheral nerve sheath tumors: Diverse drivers of Ras pathway activation. Sci. Rep. 2017;7:14992. doi: 10.1038/s41598-017-15183-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-017-15183-1</ArticleId>
            <ArticleId IdType="pmc">PMC5678116</ArticleId>
            <ArticleId IdType="pubmed">29118384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaplan H.G., Rostad S., Ross J.S., Ali S.M., Millis S.Z. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations. J. Natl. Compr. Cancer Netw. 2018;16:967–974. doi: 10.6004/jnccn.2018.7033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2018.7033</ArticleId>
            <ArticleId IdType="pubmed">30099373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang M., Wang Y., Jones S., Sausen M., McMahon K., Sharma R., Wang Q., Belzberg A.J., Chaichana K., Gallia G.L., et al.  Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors. Nat. Genet. 2014;46:1170–1172. doi: 10.1038/ng.3116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3116</ArticleId>
            <ArticleId IdType="pmc">PMC4383254</ArticleId>
            <ArticleId IdType="pubmed">25305755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee W., Teckie S., Wiesner T., Ran L., Prieto Granada C.N., Lin M., Zhu S., Cao Z., Liang Y., Sboner A., et al.  PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat. Genet. 2014;46:1227–1232. doi: 10.1038/ng.3095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.3095</ArticleId>
            <ArticleId IdType="pmc">PMC4249650</ArticleId>
            <ArticleId IdType="pubmed">25240281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moritz L.E., Trievel R.C. Structure, mechanism, and regulation of polycomb repressive complex 2. J. Biol. Chem. 2018;293:13805–13814. doi: 10.1074/jbc.R117.800367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.R117.800367</ArticleId>
            <ArticleId IdType="pmc">PMC6130931</ArticleId>
            <ArticleId IdType="pubmed">28912274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cleven A.H., Sannaa G.A., Briaire-de Bruijn I., Ingram D.R., van de Rijn M., Rubin B.P., de Vries M.W., Watson K.L., Torres K.E., Wang W.L., et al.  Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod. Pathol. 2016;29:582–590. doi: 10.1038/modpathol.2016.45.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/modpathol.2016.45</ArticleId>
            <ArticleId IdType="pmc">PMC4948583</ArticleId>
            <ArticleId IdType="pubmed">26990975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Raedt T., Beert E., Pasmant E., Luscan A., Brems H., Ortonne N., Helin K., Hornick J.L., Mautner V., Kehrer-Sawatzki H., et al.  PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514:247–251. doi: 10.1038/nature13561.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13561</ArticleId>
            <ArticleId IdType="pubmed">25119042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He S., Mansour M.R., Zimmerman M.W., Ki D.H., Layden H.M., Akahane K., Gjini E., de Groh E.D., Perez-Atayde A.R., Zhu S., et al.  Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain. Elife. 2016;5:e14713. doi: 10.7554/eLife.14713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.14713</ArticleId>
            <ArticleId IdType="pmc">PMC4900799</ArticleId>
            <ArticleId IdType="pubmed">27130733</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ki D.H., He S., Rodig S., Look A.T. Overexpression of PDGFRA cooperates with loss of NF1 and p53 to accelerate the molecular pathogenesis of malignant peripheral nerve sheath tumors. Oncogene. 2017;36:1058–1068. doi: 10.1038/onc.2016.269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/onc.2016.269</ArticleId>
            <ArticleId IdType="pmc">PMC5332555</ArticleId>
            <ArticleId IdType="pubmed">27477693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ki D.H., Oppel F., Durbin A.D., Look A.T. Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors. Oncogene. 2019;38:6585–6598. doi: 10.1038/s41388-019-0965-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-019-0965-5</ArticleId>
            <ArticleId IdType="pubmed">31444410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oppel F., Tao T., Shi H., Ross K.N., Zimmerman M.W., He S., Tong G., Aster J.C., Look A.T. Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies. PLoS Genet. 2019;15:e1008039.  doi: 10.1371/journal.pgen.1008039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pgen.1008039</ArticleId>
            <ArticleId IdType="pmc">PMC6476535</ArticleId>
            <ArticleId IdType="pubmed">30970016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Durbin A.D., Ki D.H., He S., Look A.T. Malignant Peripheral Nerve Sheath Tumors. Adv. Exp. Med. Biol. 2016;916:495–530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27165368</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gregorian C., Nakashima J., Dry S.M., Nghiemphu P.L., Smith K.B., Ao Y., Dang J., Lawson G., Mellinghoff I.K., Mischel P.S., et al.  PTEN dosage is essential for neurofibroma development and malignant transformation. Proc. Natl. Acad. Sci. USA. 2009;106:19479–19484. doi: 10.1073/pnas.0910398106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0910398106</ArticleId>
            <ArticleId IdType="pmc">PMC2765459</ArticleId>
            <ArticleId IdType="pubmed">19846776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keng V.W., Watson A.L., Rahrmann E.P., Li H., Tschida B.R., Moriarity B.S., Choi K., Rizvi T.A., Collins M.H., Wallace M.R., et al.  Conditional Inactivation of Pten with EGFR Overexpression in Schwann Cells Models Sporadic MPNST. Sarcoma. 2012;2012:620834. doi: 10.1155/2012/620834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2012/620834</ArticleId>
            <ArticleId IdType="pmc">PMC3539440</ArticleId>
            <ArticleId IdType="pubmed">23319880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huijbregts R.P., Roth K.A., Schmidt R.E., Carroll S.L. Hypertrophic neuropathies and malignant peripheral nerve sheath tumors in transgenic mice overexpressing glial growth factor beta3 in myelinating Schwann cells. J. Neurosci. 2003;23:7269–7280. doi: 10.1523/JNEUROSCI.23-19-07269.2003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.23-19-07269.2003</ArticleId>
            <ArticleId IdType="pmc">PMC6740435</ArticleId>
            <ArticleId IdType="pubmed">12917360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kazmi S.J., Byer S.J., Eckert J.M., Turk A.N., Huijbregts R.P., Brossier N.M., Grizzle W.E., Mikhail F.M., Roth K.A., Carroll S.L. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis. Am. J. Pathol. 2013;182:646–667. doi: 10.1016/j.ajpath.2012.11.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2012.11.017</ArticleId>
            <ArticleId IdType="pmc">PMC3586689</ArticleId>
            <ArticleId IdType="pubmed">23321323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brosius S.N., Turk A.N., Byer S.J., Longo J.F., Kappes J.C., Roth K.A., Carroll S.L. Combinatorial therapy with tamoxifen and trifluoperazine effectively inhibits malignant peripheral nerve sheath tumor growth by targeting complementary signaling cascades. J. Neuropathol. Exp. Neurol. 2014;73:1078–1090. doi: 10.1097/NEN.0000000000000126.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0000000000000126</ArticleId>
            <ArticleId IdType="pmc">PMC4458069</ArticleId>
            <ArticleId IdType="pubmed">25289889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ling B.C., Wu J., Miller S.J., Monk K.R., Shamekh R., Rizvi T.A., Decourten-Myers G., Vogel K.S., DeClue J.E., Ratner N. Role for the epidermal growth factor receptor in neurofibromatosis-related peripheral nerve tumorigenesis. Cancer Cell. 2005;7:65–75. doi: 10.1016/j.ccr.2004.10.016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2004.10.016</ArticleId>
            <ArticleId IdType="pmc">PMC2854500</ArticleId>
            <ArticleId IdType="pubmed">15652750</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahrmann E.P., Moriarity B.S., Otto G.M., Watson A.L., Choi K., Collins M.H., Wallace M., Webber B.R., Forster C.L., Rizzardi A.E., et al.  Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis. Am. J. Pathol. 2014;184:2082–2098. doi: 10.1016/j.ajpath.2014.04.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2014.04.006</ArticleId>
            <ArticleId IdType="pmc">PMC4076465</ArticleId>
            <ArticleId IdType="pubmed">24832557</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keng V.W., Rahrmann E.P., Watson A.L., Tschida B.R., Moertel C.L., Jessen W.J., Rizvi T.A., Collins M.H., Ratner N., Largaespada D.A. PTEN and NF1 Inactivation in Schwann Cells Produces a Severe Phenotype in the Peripheral Nervous System That Promotes the Development and Malignant Progression of Peripheral Nerve Sheath Tumors. Cancer Res. 2012;72:3405–3413. doi: 10.1158/0008-5472.CAN-11-4092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-11-4092</ArticleId>
            <ArticleId IdType="pmc">PMC3428071</ArticleId>
            <ArticleId IdType="pubmed">22700876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mo W., Chen J., Patel A., Zhang L., Chau V., Li Y., Cho W., Lim K., Xu J., Lazar A.J., et al.  CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell. 2013;152:1077–1090. doi: 10.1016/j.cell.2013.01.053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.01.053</ArticleId>
            <ArticleId IdType="pmc">PMC3594500</ArticleId>
            <ArticleId IdType="pubmed">23434321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johannessen C.M., Johnson B.W., Williams S.M., Chan A.W., Reczek E.E., Lynch R.C., Rioth M.J., McClatchey A., Ryeom S., Cichowski K. TORC1 is essential for NF1-associated malignancies. Curr. Biol. 2008;18:56–62. doi: 10.1016/j.cub.2007.11.066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2007.11.066</ArticleId>
            <ArticleId IdType="pubmed">18164202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rhodes S.D., He Y., Smith A., Jiang L., Lu Q., Mund J., Li X., Bessler W., Qian S., Dyer W., et al.  Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation. Hum. Mol. Genet. 2019;28:2752–2762. doi: 10.1093/hmg/ddz095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/hmg/ddz095</ArticleId>
            <ArticleId IdType="pmc">PMC6687955</ArticleId>
            <ArticleId IdType="pubmed">31091306</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paez-Ribes M., Gonzalez-Gualda E., Doherty G.J., Munoz-Espin D. Targeting senescent cells in translational medicine. EMBO Mol. Med. 2019;11:e10234. doi: 10.15252/emmm.201810234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/emmm.201810234</ArticleId>
            <ArticleId IdType="pmc">PMC6895604</ArticleId>
            <ArticleId IdType="pubmed">31746100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahrmann E.P., Watson A.L., Keng V.W., Choi K., Moriarity B.S., Beckmann D.A., Wolf N.K., Sarver A., Collins M.H., Moertel C.L., et al.  Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat. Genet. 2013;45:756–766. doi: 10.1038/ng.2641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.2641</ArticleId>
            <ArticleId IdType="pmc">PMC3695033</ArticleId>
            <ArticleId IdType="pubmed">23685747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J., Keng V.W., Patmore D.M., Kendall J.J., Patel A.V., Jousma E., Jessen W.J., Choi K., Tschida B.R., Silverstein K.A., et al.  Insertional Mutagenesis Identifies a STAT3/Arid1b/beta-catenin Pathway Driving Neurofibroma Initiation. Cell Rep. 2016;14:1979–1990. doi: 10.1016/j.celrep.2016.01.074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2016.01.074</ArticleId>
            <ArticleId IdType="pmc">PMC4782770</ArticleId>
            <ArticleId IdType="pubmed">26904939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laugesen A., Hojfeldt J.W., Helin K. Molecular Mechanisms Directing PRC2 Recruitment and H3K27 Methylation. Mol. Cell. 2019;74:8–18. doi: 10.1016/j.molcel.2019.03.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2019.03.011</ArticleId>
            <ArticleId IdType="pmc">PMC6452890</ArticleId>
            <ArticleId IdType="pubmed">30951652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Streubel G., Watson A., Jammula S.G., Scelfo A., Fitzpatrick D.J., Oliviero G., McCole R., Conway E., Glancy E., Negri G.L., et al.  The H3K36me2 Methyltransferase Nsd1 Demarcates PRC2-Mediated H3K27me2 and H3K27me3 Domains in Embryonic Stem Cells. Mol. Cell. 2018;70:371–379 e375. doi: 10.1016/j.molcel.2018.02.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2018.02.027</ArticleId>
            <ArticleId IdType="pubmed">29606589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogel K.S., Klesse L.J., Velasco-Miguel S., Meyers K., Rushing E.J., Parada L.F. Mouse tumor model for neurofibromatosis type 1. Science. 1999;286:2176–2179. doi: 10.1126/science.286.5447.2176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.286.5447.2176</ArticleId>
            <ArticleId IdType="pmc">PMC3079436</ArticleId>
            <ArticleId IdType="pubmed">10591653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cichowski K., Shih T.S., Schmitt E., Santiago S., Reilly K., McLaughlin M.E., Bronson R.T., Jacks T. Mouse models of tumor development in neurofibromatosis type 1. Science. 1999;286:2172–2176. doi: 10.1126/science.286.5447.2172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.286.5447.2172</ArticleId>
            <ArticleId IdType="pubmed">10591652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reilly K.M., Tuskan R.G., Christy E., Loisel D.A., Ledger J., Bronson R.T., Smith C.D., Tsang S., Munroe D.J., Jacks T. Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects. Proc. Natl. Acad. Sci. USA. 2004;101:13008–13013. doi: 10.1073/pnas.0401236101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0401236101</ArticleId>
            <ArticleId IdType="pmc">PMC516509</ArticleId>
            <ArticleId IdType="pubmed">15319471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malone C.F., Fromm J.A., Maertens O., DeRaedt T., Ingraham R., Cichowski K. Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers. Cancer Discov. 2014;4:1062–1073. doi: 10.1158/2159-8290.CD-14-0159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-14-0159</ArticleId>
            <ArticleId IdType="pmc">PMC4446704</ArticleId>
            <ArticleId IdType="pubmed">24913553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maertens O., McCurrach M.E., Braun B.S., De Raedt T., Epstein I., Huang T.Q., Lauchle J.O., Lee H., Wu J., Cripe T.P., et al.  A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. Cancer Res. 2017;77:5706–5711. doi: 10.1158/0008-5472.CAN-17-1789.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-17-1789</ArticleId>
            <ArticleId IdType="pmc">PMC5668167</ArticleId>
            <ArticleId IdType="pubmed">28993414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malone C.F., Emerson C., Ingraham R., Barbosa W., Guerra S., Yoon H., Liu L.L., Michor F., Haigis M., Macleod K.F., et al.  mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors. Cancer Discov. 2017;7:1450–1463. doi: 10.1158/2159-8290.CD-17-0177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-17-0177</ArticleId>
            <ArticleId IdType="pmc">PMC5718976</ArticleId>
            <ArticleId IdType="pubmed">28963352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lock R., Ingraham R., Maertens O., Miller A.L., Weledji N., Legius E., Konicek B.M., Yan S.C., Graff J.R., Cichowski K. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers. J. Clin. Invest. 2016;126:2181–2190. doi: 10.1172/JCI85183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI85183</ArticleId>
            <ArticleId IdType="pmc">PMC4887164</ArticleId>
            <ArticleId IdType="pubmed">27159396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dodd R.D., Mito J.K., Eward W.C., Chitalia R., Sachdeva M., Ma Y., Barretina J., Dodd L., Kirsch D.G. NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition. Mol. Cancer. 2013;12:1906–1917. doi: 10.1158/1535-7163.MCT-13-0189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-13-0189</ArticleId>
            <ArticleId IdType="pmc">PMC3825462</ArticleId>
            <ArticleId IdType="pubmed">23858101</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dodd R.D., Lee C.L., Overton T., Huang W., Eward W.C., Luo L., Ma Y., Ingram D.R., Torres K.E., Cardona D.M., et al.  NF1(+/−) Hematopoietic Cells Accelerate Malignant Peripheral Nerve Sheath Tumor Development without Altering Chemotherapy Response. Cancer Res. 2017;77:4486–4497. doi: 10.1158/0008-5472.CAN-16-2643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-2643</ArticleId>
            <ArticleId IdType="pmc">PMC5839126</ArticleId>
            <ArticleId IdType="pubmed">28646022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J., Chen M., Whitley M.J., Kuo H.C., Xu E.S., Walens A., Mowery Y.M., Van Mater D., Eward W.C., Cardona D.M., et al.  Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma. Nat. Commun. 2017;8:15999. doi: 10.1038/ncomms15999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms15999</ArticleId>
            <ArticleId IdType="pmc">PMC5508130</ArticleId>
            <ArticleId IdType="pubmed">28691711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fang Y., Elahi A., Denley R.C., Rao P.H., Brennan M.F., Jhanwar S.C. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1. Anticancer Res. 2009;29:1255–1262.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19414372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun D., Tainsky M.A., Haddad R. Oncogene Mutation Survey in MPNST Cell Lines Enhances the Dominant Role of Hyperactive Ras in NF1 Associated Pro-Survival and Malignancy. Transl Oncogenomics. 2012;5:1–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3273949</ArticleId>
            <ArticleId IdType="pubmed">22346343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Castellsague J., Gel B., Fernandez-Rodriguez J., Llatjos R., Blanco I., Benavente Y., Perez-Sidelnikova D., Garcia-Del Muro J., Vinals J.M., Vidal A., et al.  Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. Embo Mol. Med. 2015;7:608–627. doi: 10.15252/emmm.201404430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/emmm.201404430</ArticleId>
            <ArticleId IdType="pmc">PMC4492820</ArticleId>
            <ArticleId IdType="pubmed">25810463</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollard K., Banerjee J., Doan X., Wang J., Guo X., Allaway R., Langmead S., Slobogean B., Meyer C.F., Loeb D.M. A clinically and genomically annotated nerve sheath tumor biospecimen repository. biorxiv. :2020. doi: 10.1101/2019.12.19.871897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2019.12.19.871897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rutkowski J.L., Kirk C.J., Lerner M.A., Tennekoon G.I. Purification and expansion of human Schwann cells in vitro. Nat. Med. 1995;1:80–83. doi: 10.1038/nm0195-80.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm0195-80</ArticleId>
            <ArticleId IdType="pubmed">7584959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H., Chang L.J., Neubauer D.R., Muir D.F., Wallace M.R. Immortalization of human normal and NF1 neurofibroma Schwann cells. Lab. Invest. 2016;96:1105–1115. doi: 10.1038/labinvest.2016.88.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/labinvest.2016.88</ArticleId>
            <ArticleId IdType="pubmed">27617404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watson A.L., Rahrmann E.P., Moriarity B.S., Choi K., Conboy C.B., Greeley A.D., Halfond A.L., Anderson L.K., Wahl B.R., Keng V.W., et al.  Canonical Wnt/beta-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. Cancer Discov. 2013;3:674–689. doi: 10.1158/2159-8290.CD-13-0081.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-13-0081</ArticleId>
            <ArticleId IdType="pmc">PMC3679355</ArticleId>
            <ArticleId IdType="pubmed">23535903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carrio M., Mazuelas H., Richaud-Patin Y., Gel B., Terribas E., Rosas I., Jimenez-Delgado S., Biayna J., Vendredy L., Blanco I., et al.  Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas. Stem. Cell Rep. 2019;12:411–426. doi: 10.1016/j.stemcr.2019.01.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.stemcr.2019.01.001</ArticleId>
            <ArticleId IdType="pmc">PMC6373434</ArticleId>
            <ArticleId IdType="pubmed">30713041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dobzhansky T. Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura. Genetics. 1946;31:269–290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1209328</ArticleId>
            <ArticleId IdType="pubmed">20985721</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hartwell L.H., Szankasi P., Roberts C.J., Murray A.W., Friend S.H. Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997;278:1064–1068. doi: 10.1126/science.278.5340.1064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.278.5340.1064</ArticleId>
            <ArticleId IdType="pubmed">9353181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N.J., Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–917. doi: 10.1038/nature03443.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature03443</ArticleId>
            <ArticleId IdType="pubmed">15829966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Javle M., Curtin N.J. The role of PARP in DNA repair and its therapeutic exploitation. Br. J. Cancer. 2011;105:1114–1122. doi: 10.1038/bjc.2011.382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2011.382</ArticleId>
            <ArticleId IdType="pmc">PMC3208503</ArticleId>
            <ArticleId IdType="pubmed">21989215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang A., Garraway L.A., Ashworth A., Weber B. Synthetic lethality as an engine for cancer drug target discovery. Nat. Rev. Drug Discov. 2020;9:23–38. doi: 10.1038/s41573-019-0046-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41573-019-0046-z</ArticleId>
            <ArticleId IdType="pubmed">31712683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Semenova G., Stepanova D.S., Deyev S.M., Chernoff J. Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1. Biochimie. 2017;135:1–5. doi: 10.1016/j.biochi.2017.01.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.biochi.2017.01.001</ArticleId>
            <ArticleId IdType="pmc">PMC5405558</ArticleId>
            <ArticleId IdType="pubmed">28065690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrer M., Gosline S.J.C., Stathis M., Zhang X., Guo X., Guha R., Ryman D.A., Wallace M.R., Kasch-Semenza L., Hao H., et al.  Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells. Sci. Data. 2018;5:180106. doi: 10.1038/sdata.2018.106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sdata.2018.106</ArticleId>
            <ArticleId IdType="pmc">PMC5996849</ArticleId>
            <ArticleId IdType="pubmed">29893754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dombi E., Baldwin A., Marcus L.J., Fisher M.J., Weiss B., Kim A., Whitcomb P., Martin S., Aschbacher-Smith L.E., Rizvi T.A., et al.  Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. N. Engl. J. Med. 2016;375:2550–2560. doi: 10.1056/NEJMoa1605943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1605943</ArticleId>
            <ArticleId IdType="pmc">PMC5508592</ArticleId>
            <ArticleId IdType="pubmed">28029918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCowage G.B., Pratilas C.A., Hargrave D.R., Moertel C.L., Whitlock J., Fox E., Hingorani P., Russo M.W., Dasgupta K., Tseng L., et al.  Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)–associated plexiform neurofibroma: A phase I/IIa study. J. Clin. Oncol. 2018;36:10504. doi: 10.1200/JCO.2018.36.15_suppl.10504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.10504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gross A.M., Wolters P.L., Dombi E., Baldwin A., Whitcomb P., Fisher M.J., Weiss B., Kim A., Bornhorst M., Shah A.C., et al.  Selumetinib in Children with Inoperable Plexiform Neurofibromas. N. Engl. J. Med. 2020;382:1430–1442. doi: 10.1056/NEJMoa1912735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1912735</ArticleId>
            <ArticleId IdType="pmc">PMC7305659</ArticleId>
            <ArticleId IdType="pubmed">32187457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Daud A., Tsai K. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. Oncologist. 2017;22:823–833. doi: 10.1634/theoncologist.2016-0456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2016-0456</ArticleId>
            <ArticleId IdType="pmc">PMC5507648</ArticleId>
            <ArticleId IdType="pubmed">28526719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stalnecker C.A., Der C.J. RAS, wanted dead or alive: Advances in targeting RAS mutant cancers. Sci. Signal. 2020:13. doi: 10.1126/scisignal.aay6013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scisignal.aay6013</ArticleId>
            <ArticleId IdType="pmc">PMC7393681</ArticleId>
            <ArticleId IdType="pubmed">32209699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim H.A., Ling B., Ratner N. Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: Reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol. Cell Biol. 1997;17:862–872. doi: 10.1128/MCB.17.2.862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.17.2.862</ArticleId>
            <ArticleId IdType="pmc">PMC231813</ArticleId>
            <ArticleId IdType="pubmed">9001241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dilworth J.T., Wojtkowiak J.W., Mathieu P., Tainsky M.A., Reiners J.J., Jr., Mattingly R.R., Hancock C.N. Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033. Cancer Biol. 2008;7:1938–1946. doi: 10.4161/cbt.7.12.6942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cbt.7.12.6942</ArticleId>
            <ArticleId IdType="pmc">PMC3923431</ArticleId>
            <ArticleId IdType="pubmed">18927496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wojtkowiak J.W., Fouad F., LaLonde D.T., Kleinman M.D., Gibbs R.A., Reiners J.J., Jr., Borch R.F., Mattingly R.R. Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. J. Pharm. Exp. 2008;326:1–11. doi: 10.1124/jpet.107.135830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/jpet.107.135830</ArticleId>
            <ArticleId IdType="pmc">PMC3768167</ArticleId>
            <ArticleId IdType="pubmed">18367665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Widemann B.C., Salzer W.L., Arceci R.J., Blaney S.M., Fox E., End D., Gillespie A., Whitcomb P., Palumbo J.S., Pitney A., et al.  Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J. Clin. Oncol. 2006;24:507–516. doi: 10.1200/JCO.2005.03.8638.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2005.03.8638</ArticleId>
            <ArticleId IdType="pubmed">16421428</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Widemann B.C., Dombi E., Gillespie A., Wolters P.L., Belasco J., Goldman S., Korf B.R., Solomon J., Martin S., Salzer W., et al.  Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro. Oncol. 2014;16:707–718. doi: 10.1093/neuonc/nou004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nou004</ArticleId>
            <ArticleId IdType="pmc">PMC3984559</ArticleId>
            <ArticleId IdType="pubmed">24500418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fangusaro J., Onar-Thomas A., Young Poussaint T., Wu S., Ligon A.H., Lindeman N., Banerjee A., Packer R.J., Kilburn L.B., Goldman S., et al.  Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: A multicentre, phase 2 trial. Lancet. Oncol. 2019;20:1011–1022. doi: 10.1016/S1470-2045(19)30277-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(19)30277-3</ArticleId>
            <ArticleId IdType="pmc">PMC6628202</ArticleId>
            <ArticleId IdType="pubmed">31151904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weiss B., Widemann B.C., Wolters P., Dombi E., Vinks A., Cantor A., Perentesis J., Schorry E., Ullrich N., Gutmann D.H., et al.  Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: A neurofibromatosis Clinical Trials Consortium phase II study. Neuro. Oncol. 2015;17:596–603. doi: 10.1093/neuonc/nou235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nou235</ArticleId>
            <ArticleId IdType="pmc">PMC4483073</ArticleId>
            <ArticleId IdType="pubmed">25314964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varin J., Poulain L., Hivelin M., Nusbaum P., Hubas A., Laurendeau I., Lantieri L., Wolkenstein P., Vidaud M., Pasmant E., et al.  Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells. Oncotarget. 2016;7:35753–35767. doi: 10.18632/oncotarget.7099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.7099</ArticleId>
            <ArticleId IdType="pmc">PMC5094959</ArticleId>
            <ArticleId IdType="pubmed">26840085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim A., Lu Y., Okuno S.H., Reinke D., Maertens O., Perentesis J., Basu M., Wolters P.L., De Raedt T., Chawla S., et al.  Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023) Sarcoma. 2020;2020:5784876. doi: 10.1155/2020/5784876.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2020/5784876</ArticleId>
            <ArticleId IdType="pmc">PMC7013290</ArticleId>
            <ArticleId IdType="pubmed">32089640</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Raedt T., Walton Z., Yecies J.L., Li D., Chen Y., Malone C.F., Maertens O., Jeong S.M., Bronson R.T., Lebleu V., et al.  Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell. 2011;20:400–413. doi: 10.1016/j.ccr.2011.08.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2011.08.014</ArticleId>
            <ArticleId IdType="pmc">PMC3233475</ArticleId>
            <ArticleId IdType="pubmed">21907929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Widemann B.C., Lu Y., Reinke D., Okuno S.H., Meyer C.F., Cote G.M., Chugh R., Milhem M.M., Hirbe A.C., Kim A., et al.  Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016) Sarcoma. 2019;2019:7656747. doi: 10.1155/2019/7656747.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2019/7656747</ArticleId>
            <ArticleId IdType="pmc">PMC6681622</ArticleId>
            <ArticleId IdType="pubmed">31427883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Patwardhan P.P., Surriga O., Beckman M.J., de Stanchina E., Dematteo R.P., Tap W.D., Schwartz G.K. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin. Cancer Res. 2014;20:3146–3158. doi: 10.1158/1078-0432.CCR-13-2576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-2576</ArticleId>
            <ArticleId IdType="pmc">PMC4060793</ArticleId>
            <ArticleId IdType="pubmed">24718867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kolberg M., Bruun J., Murumagi A., Mpindi J.P., Bergsland C.H., Holand M., Eilertsen I.A., Danielsen S.A., Kallioniemi O., Lothe R.A. Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors. Mol. Oncol. 2017;11:1156–1171. doi: 10.1002/1878-0261.12086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1878-0261.12086</ArticleId>
            <ArticleId IdType="pmc">PMC5579334</ArticleId>
            <ArticleId IdType="pubmed">28556483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kohlmeyer J.L., Kaemmer C.A., Pulliam C., Maharjan C.K., Moreno Samayoa A., Major H.J., Cornick K.E., Knepper-Adrian V., Khanna R., Sieren J.C., et al.  RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4/6 inhibitors. Clin. Cancer Res. :2020. doi: 10.1158/1078-0432.CCR-19-2706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-2706</ArticleId>
            <ArticleId IdType="pmc">PMC7299809</ArticleId>
            <ArticleId IdType="pubmed">32086342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wojcik J.B., Marchione D.M., Sidoli S., Djedid A., Lisby A., Majewski J., Garcia B.A. Epigenomic reordering induced by Polycomb loss drives oncogenesis but leads to therapeutic vulnerabilities in malignant peripheral nerve sheath tumors. Cancer Res. 2019 doi: 10.1158/0008-5472.CAN-18-3704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-18-3704</ArticleId>
            <ArticleId IdType="pmc">PMC6637743</ArticleId>
            <ArticleId IdType="pubmed">30898839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frankowski K.J., Wang C., Patnaik S., Schoenen F.J., Southall N., Li D., Teper Y., Sun W., Kandela I., Hu D., et al.  Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis. Sci. Transl. Med. 2018:10. doi: 10.1126/scitranslmed.aap8307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aap8307</ArticleId>
            <ArticleId IdType="pmc">PMC6176865</ArticleId>
            <ArticleId IdType="pubmed">29769289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nair J.S., Musi E., Schwartz G.K. Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of IkappaB and Downregulation of Survivin. Clin. Cancer Res. 2017;23:4301–4311. doi: 10.1158/1078-0432.CCR-16-2632.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-2632</ArticleId>
            <ArticleId IdType="pubmed">28314790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahller Y.Y., Rangwala F., Ratner N., Cripe T.P. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. Pediatr Blood Cancer. 2006;46:745–754. doi: 10.1002/pbc.20565.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/pbc.20565</ArticleId>
            <ArticleId IdType="pubmed">16124003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Farassati F., Pan W., Yamoutpour F., Henke S., Piedra M., Frahm S., Al-Tawil S., Mangrum W.I., Parada L.F., Rabkin S.D., et al.  Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes. Am. J. Pathol. 2008;173:1861–1872. doi: 10.2353/ajpath.2008.080376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2353/ajpath.2008.080376</ArticleId>
            <ArticleId IdType="pmc">PMC2626396</ArticleId>
            <ArticleId IdType="pubmed">18988803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antoszczyk S., Spyra M., Mautner V.F., Kurtz A., Stemmer-Rachamimov A.O., Martuza R.L., Rabkin S.D. Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro Oncol. 2014;16:1057–1066. doi: 10.1093/neuonc/not317.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/not317</ArticleId>
            <ArticleId IdType="pmc">PMC4096170</ArticleId>
            <ArticleId IdType="pubmed">24470552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deyle D.R., Escobar D.Z., Peng K.W., Babovic-Vuksanovic D. Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors. Genes. 2015;565:140–145. doi: 10.1016/j.gene.2015.04.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gene.2015.04.001</ArticleId>
            <ArticleId IdType="pubmed">25843626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson J.D., Markert J.M., Li L., Carroll S.L., Cassady K.A. STAT1 and NF-kappaB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells. Mol. Cancer Res. 2016;14:482–492. doi: 10.1158/1541-7786.MCR-15-0427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-15-0427</ArticleId>
            <ArticleId IdType="pmc">PMC4867290</ArticleId>
            <ArticleId IdType="pubmed">26883073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Currier M.A., Sprague L., Rizvi T.A., Nartker B., Chen C.Y., Wang P.Y., Hutzen B.J., Franczek M.R., Patel A.V., Chaney K.E., et al.  Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation. Oncotarget. 2017;8:17412–17427. doi: 10.18632/oncotarget.14885.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.14885</ArticleId>
            <ArticleId IdType="pmc">PMC5392259</ArticleId>
            <ArticleId IdType="pubmed">28147331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ghonime M.G., Cassady K.A. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy. Cancer Immunol. Res. 2018;6:1499–1510. doi: 10.1158/2326-6066.CIR-18-0014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-18-0014</ArticleId>
            <ArticleId IdType="pubmed">30352799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robertson K.A., Nalepa G., Yang F.C., Bowers D.C., Ho C.Y., Hutchins G.D., Croop J.M., Vik T.A., Denne S.C., Parada L.F., et al.  Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: A phase 2 trial. Lancet. Oncol. 2012;13:1218–1224. doi: 10.1016/S1470-2045(12)70414-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(12)70414-X</ArticleId>
            <ArticleId IdType="pmc">PMC5380388</ArticleId>
            <ArticleId IdType="pubmed">23099009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo J., Grovola M.R., Xie H., Coggins G.E., Duggan P., Hasan R., Huang J., Lin D.W., Song C., Witek G.M., et al.  Comprehensive pharmacological profiling of neurofibromatosis cell lines. Am. J. Cancer Res. 2017;7:923–934.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5411799</ArticleId>
            <ArticleId IdType="pubmed">28469964</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
